MAIA Biotechnology, Inc.
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$22.4M
- Total assets
- $9.7M
- Market cap
- $82.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $24.3M
- Operating income
- -$24.3M
- Income tax
- $2.0K
- Net income
- -$22.4M
- EPS (basic)
- $-0.70
- EPS (diluted)
- $-0.70
Balance sheet
- Total assets
- $9.7M
- Current assets
- $9.7M
- Total liabilities
- $7.3M
- Current liabilities
- $5.8M
- Shareholders’ equity
- $2.4M
Cash flow
- Operating cash flow
- -$18.8M
- Investing cash flow
- $938.1K
- Financing cash flow
- $17.9M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $82.7M
- EPS (diluted)
- $-0.7
- Shares outstanding
- 65.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 28, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.4M in FY2024.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MAIA Biotechnology, Inc..
Write a review
News about MAIA Biotechnology, Inc.
News & sentiment via Polygon.io
